Commence the potentially pivotal Phase 2 clinical trial of Berubicin in adults
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Potentially Pivotal Phase 2 clinical trial expected to commence in Q1 2021”
What we found
Evidence strength A What the grades mean
The company's Q1 2021 target slipped. A May 2021 filing said it intended to start in Q2 2021, and a July 2021 filing reported the potentially pivotal glioblastoma study was initiated in May 2021.
-
A CNS Pharmaceuticals, Inc. 10-Q filed 2021-05-13
“We intend to initiate our trial during the second quarter of 2021 to investigate the efficacy of Berubicin in adults with Glioblastoma Multiforme who have failed first-line therapy.” ✓ confirmed on the page
-
A CNS Pharmaceuticals, Inc. 8-K filed 2021-07-19
“Initiated potentially pivotal study in lead indication, glioblastoma, in May 2021” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Commence
- Deliverable
- Potentially pivotal U.S. Phase 2 Berubicin trial for GBM
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you CNS Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CNSP-024695 · Corrections policy